GET DAILY SIGNALSCardinal Health (CAH): Assessing the Path to a $300 Target With +10% Upside
Key Takeaways
- The central $300 target is the rounded average of verified analyst price targets above the current share price, not the all-analyst mean.
- At about $271.72, reaching $300 implies roughly 10% upside — a modest but still meaningful move.
- The overall mean of all reviewed targets is roughly $292, with a range from about $260 (Bank of America) to $330 (Leerink Partners).
- Strongest support: raised fiscal 2027 adjusted EPS guidance to $12.80–$13.00 and double-digit pharmaceutical profit growth.
- Biggest risk: an elevated valuation (P/E near 35) and thin margins, plus medical-segment cost pressure.
- Street sentiment skews positive, with roughly 16 Buy or equivalent ratings against a handful of Hold ratings and no Sell ratings.
- For additional context, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots for AI-driven market insights.
Analyst Price Targets and Consensus View
Reviewing roughly a dozen recent, individually attributable analyst targets produced an overall average near $292, spanning approximately $260 to $330. Because that overall mean sits only about 7% above the current price — below the 10% threshold that makes a target meaningful for this exercise — the $300 central target here is the average of the verified targets above the current price, which works out to about $297 before rounding. This is not an official published consensus; independent trackers report similar figures, with S&P Global data near $291 and a FactSet median around $290. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent moves cluster in the high $200s to low $300s: UBS raised its target to $310, Morgan Stanley to $306, Baird to $305, RBC Capital to $295, and Mizuho to $290. At the bullish end, Leerink Partners lifted its target to $330, and Evercore ISI adjusted its target to $320. More cautious views include Barclays at $275, Wells Fargo at $277, and Citi and TD Cowen at $280. The spread reflects disagreement about how much premium the market should pay for Cardinal Health's improving mix toward higher-margin specialty distribution.
Current Market Position and Path Toward the Target
With shares around $271.72, moving to $300 requires an advance of roughly 10.4% — a modest move by equity-market standards, but one that would take the stock decisively above its recent 52-week high near $286. The path runs through continued execution in the pharmaceutical and specialty-solutions segment, where management raised full-year segment profit growth guidance to 10%–12% from 8%–11% and lifted fiscal 2027 non-GAAP diluted EPS guidance to $12.80–$13.00 from $12.40–$12.60. GLP-1 medications added about five percentage points to pharmaceutical revenue growth, partly offset by an Inflation Reduction Act headwind.
What Could Support a Move Toward the Target
Cardinal Health's fiscal first-quarter results beat expectations, with adjusted EPS of $3.26 versus a roughly $2.94 consensus and revenue of $67.51 billion, up about 5.5% year over year. The company completed a $500 million share repurchase during the quarter and has renewed contracts covering a large share of revenue, including an extension of its relationship with CVS Health through 2032. Demand strength in generics, oncology, and urology specialty therapies, combined with margin expansion in the pharmaceutical segment, underpins the constructive analyst revisions. A defensive, non-AI business profile has also attracted flows as investors rotate away from crowded technology trades.
What Could Prevent the Target From Being Reached
The stock trades at a P/E near 35 on trailing earnings, a premium multiple for a low-margin distributor, leaving limited room for multiple expansion. Medical-segment profit is trending toward the low end of its $200–$220 million forecast because of elevated petroleum and commodity costs. Longer-standing overhangs include opioid-related litigation risk and historical segment volatility. If pharmaceutical profit growth decelerates in the middle of the fiscal year as management has signaled, or if the Inflation Reduction Act headwind intensifies, analysts could trim targets rather than raise them.
Technical Levels and Market Structure
The recent 52-week high near $286 stands as the nearest meaningful resistance zone; a sustained move above it would open the path toward the psychologically important $300 level. On the downside, support has formed near the $260–$264 area, where shares have found buyers on recent pullbacks. The broader structure remains constructive, with the stock well above its 52-week low near $180, but $300 would represent new all-time-high territory that has not yet been tested. From what I see, the technical setup aligns with the fundamental drivers outlined above.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. The most important upcoming catalysts are the company's quarterly earnings and any further changes to fiscal 2027 guidance, particularly in the pharmaceutical and specialty-solutions segment. Investors should also watch analyst target revisions, medical-segment cost trends, contract renewals, and any regulatory or litigation developments tied to drug pricing or opioids. A sustained break above the prior high near $286 would be the clearest technical confirmation of a move toward $300.
Final Assessment
The $300 target for Cardinal Health reflects the average of analyst price targets above the current share price, a figure modestly above the broader all-analyst mean near $292. Reaching it requires roughly 10% upside from about $271.72, which is achievable in principle but not guaranteed. Support comes from raised earnings guidance, specialty and generic demand strength, contract renewals, and a defensive business profile, while a premium valuation, thin margins, medical-segment cost pressure, and litigation overhang are the principal obstacles. With analyst targets spanning $260 to $330, the dispersion shows genuine disagreement about how much the market will pay for the company's improving mix. The next earnings report, guidance updates, and a move through the $286 prior high will be the clearest signals of whether $300 is in reach.
Leveraging AI Daily Buy/Sell Signals in My Process
In my own research, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor shifts across thousands of stocks and ETFs. The tool generates Buy, Sell, or Hold signals using AI analysis of technical behavior and market conditions, helping me layer data-driven insights onto fundamental work like this without replacing it. It has added efficiency when tracking names such as Cardinal Health amid evolving trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CAH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CAH turned positive on November 04, 2026. Looking at past instances where CAH's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CAH as a result. In 66 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 262 of 392 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 58 cases where CAH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-21.824) is normal, around the industry mean (14.423). CAH has a moderately high P/E Ratio (37.376) as compared to the industry average of (11.188). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.134) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement